

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/515,513	02/29/2000	Wu Bo Li	0942.4870001/RWE	1139	
26111 75	590 06/10/2004		EXAM	EXAMINER	
STERNE, KESSLER, GOLDSTEIN & FOX PLLC 1100 NEW YORK AVENUE, N.W. WASHINGTON, DC 20005			SISSON, BRADLEY L		
			ART UNIT	PAPER NUMBER	
			1634		

DATE MAILED: 06/10/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
Advisory Action	09/515,513	LI ET AL.			
Advisory Action	Examiner	Art Unit			
	Bradley L. Sisson	1634			
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence address			
THE REPLY FILED 21 May 2004 FAILS TO PLACE TH Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may <u>only</u> be either: (condition for allowance; (2) a timely filed Notice of Appe Examination (RCE) in compliance with 37 CFR 1.114.	void abandonment of this applicable in the sapplication of this application in a same of this application and the same of this application and the same of the sam	cation. A proper reply to a ch places the application in			
PERIOD FOR RE	PLY [check either a) or b)]				
a) The period for reply expiresmonths from the mailing of the period for reply expires on: (1) the mailing date of this Advance, however, will the statutory period for reply expire later the ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The data have been filed is the date for purposes of determining the period of extensions of the shortened of the short	risory Action, or (2) the date set forth in th an SIX MONTHS from the mailing date o FILED WITHIN TWO MONTHS OF TH te on which the petition under 37 CFR 1.1 sion and the corresponding amount of the	f the final rejection. E FINAL REJECTION. See MPEP 136(a) and the appropriate extension fee fee. The appropriate extension fee under			
 above, if checked. Any reply received by the Office later than three more earned patent term adjustment. See 37 CFR 1.704(b). 	onths after the mailing date of the final rej	ection, even if timely filed, may reduce any			
 A Notice of Appeal was filed on <u>21 May 2004</u>. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal. 					
2. The proposed amendment(s) will not be entered b					
(a) they raise new issues that would require furth		(see NOTE below);			
(b) they raise the issue of new matter (see Note below);					
(c) they are not deemed to place the application issues for appeal; and/or	in better form for appeal by mat	erially reducing or simplifying the			
(d) they present additional claims without cance	ling a corresponding number of	finally rejected claims.			
NOTE: See Continuation Sheet.					
3. Applicant's reply has overcome the following rejection.					
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	I be allowable if submitted in a s	separate, timely filed amendment			
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because: _		sidered but does NOT place the			
6. The affidavit or exhibit will NOT be considered be raised by the Examiner in the final rejection.	cause it is not directed SOLELY	to issues which were newly			
7. For purposes of Appeal, the proposed amendmen explanation of how the new or amended claims w					
The status of the claim(s) is (or will be) as follows	:				
Claim(s) allowed:					
Claim(s) objected to: 47-50,53-63 and 106.					
Claim(s) rejected: <u>51,52 and 107</u> .					
Claim(s) withdrawn from consideration:					
8. The drawing correction filed on is a) app	proved or b)☐ disapproved by	the Examiner.			
9. Note the attached Information Disclosure Statement	ent(s)(PTO-1449) Paper No(s).	·			
10. Other:		B. F. Line			
		Bradley L. Sisson Primary Examiner Art Unit: 1634			

U.S. Patent and Trademark Office PTOL-303 (Rev. 11-03) Continuation of 2. NOTE: The aspect of inhibiting a particular activity of the polypeptide, i.e., the reverse transcriptase activity, would raise a new issue that would require further consideration and/or search.